A Feasibility Study to Further the Development of Lung Cancer-based Precision Medicine
The purpose of this study is to further advancements in biospecimens (blood cellular free component, e.g., plasma, serum, tissue, urine), in order to develop precision medicine, for lung cancer management and lung cancer screening (synergy with imaging). A co-clinical trial approach, with integrative analyses leveraging data from the treatment of genetic mouse models of lung cancer along with clinical samples and data from lung cancer patients, will be used to elucidate genomic background metrics, identify cell free DNA mutations, and further refine the liquid biopsy approach. Blood and urine samples will be analyzed for different genetic components. The tissue biopsy will be implanted into a mouse and after the cancer grows in the mouse the cancer DNA from the mouse will be compared with the human blood.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated May 29, 2026 · Source: ClinicalTrials.gov
The study is underway but is not accepting new participants.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Basic Science
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- University of Arkansas
- Interventions being studied
- Other: Fresh tissue biopsy; Other: Blood/Urine Sample Collection
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
Cohort A (Lung/Head and Neck Cancer Group) 1. Unresectable metastatic lung cancer or head and neck cancer or other solid tumor malignancy 2. Current or Former Smokers with greater than or equal to 10 pack year smoking history 3. Candidates for standard or experimental treatment as determined by their treating physician 4. Age 18 years and older 5. Must sign an informed consent approved by the UAMS Institutional Review Board (IRB) Cohort A (Lung/Head and Neck Cancer Group)
- 1. Any other significant medical or psychiatric conditions which, in the opinion of the enrolling investigator, may interfere with consent or compliance of the treatment regimen 2. Existing diagnosis or evidence of Hepatits C, Rheumatoid Arthritis or any previous solid organ transplant. 3. Existing diagnosis or evidence of organic brain syndrome that might preclude participation in the full protocol 4. Existing diagnosis or history of significant impairment of basal cognitive function that might preclude participation in the full protocol 5. Other significant medical or psychiatric conditions which, in the opinion of the enrolling investigator, may interfere with consent or compliance of the treatment regimen Cohort B (Chronic Inflammatory disease) Inclusion criteria: 1. Chronic inflammatory disease including but not limited to:
- Systematic Lupus Erythematosus
- Rheumatoid arthritis
- Hepatitis C
- Ankylosing Sponsylitis
- Scleroderma 2. No history of smoking or quit smoking within the last six months 3. Age 18 years and older 4. Must sign an informed consent approved by the UAMS Institutional Review Board (IRB) Cohort B (Chronic inflammatory disease)
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Arkansas for Medical SciencesLittle Rock, Arkansas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 29, 2026. Always confirm current availability with the study team.